TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

References

• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544.
   PubMed Web of Science ®Google Scholar
• Ardolino M, Zingoni A, Cerboni C, et al. (2011). DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood, 117(18), 4778–4786.
   PubMed Web of Science ®Google Scholar
• Bernhardt G. (2014). TACTILE becomes tangible: CD96 discloses its inhibitory peculiarities. Nat Immunol, 15(5), 406–408.
   PubMed Web of Science ®Google Scholar
• Bevelacqua V, Bevelacqua Y, Candido S, et al. (2012). Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget, 3(8), 882–892.
   PubMed Web of Science ®Google Scholar
• Bin Dhuban K, d’Hennezel E, Nashi E, et al. (2015). Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells. J Immunol, 194(8), 3687–3696.
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Haining WN, et al. (2009). Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol, 10(1), 29–37.
   PubMed Web of Science ®Google Scholar
• Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. (2006). Human T cell responses against melanoma. Annu Rev Immunol, 24, 175–208.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Norell H, Bryceson YT, et al. (2009). Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol, 183(8), 4921–4930.
   PubMed Web of Science ®Google Scholar
• Casado JG, Pawelec G, Morgado S, et al. (2009). Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother CII, 58(9), 1517–1526.
   Google Scholar
• Chan CJ, Martinet L, Gilfillan S, et al. (2014). The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol, 15(5), 431–438.
   PubMed Web of Science ®Google Scholar
• Chan CJ, Smyth MJ, Martinet L. (2014). Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ, 21(1), 5–14.
   Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, et al. (2015). TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest, 125(5), 2046–2058.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1–10.
   Google Scholar
• Chen L, Flies DB. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 13(4), 227–242.
   PubMed Web of Science ®Google Scholar
• Chen L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 4(5), 336–347.
   PubMed Web of Science ®Google Scholar
• Chodon T, Koya RC, Odunsi K. (2015). Active immunotherapy of cancer. Immunol Invest, 44(8), 817–836.
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, et al. (2013). T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol, 25(2), 214–221.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny YM, Meade JL, Holmes TD, et al. (2007). The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res, 67(18), 8444–8449.
   PubMed Web of Science ®Google Scholar
• Ferraro A, D’Alise AM, Raj T, et al. (2014). Interindividual variation in human T regulatory cells. Proc Natl Acad Sci USA, 111(12), E1111–E1120.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. (2009). Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev, 224, 166–182.
   Web of Science ®Google Scholar
• Fourcade J, Kudela P, Sun Z, et al. (2009). PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol, 182(9), 5240–5249.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med, 207(10), 2175–2186.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, et al. (2012). CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res, 72(4), 887–896.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Cella M, Giurisato E, et al. (2004). Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172(7), 3994–3998.
   PubMed Web of Science ®Google Scholar
• Fuhrman CA, Yeh WI, Seay HR, et al. (2015). Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol, 195(1), 145–155.
   PubMed Web of Science ®Google Scholar
• Georgiev H, Danisch S, Chambers BJ, et al. (2014). To the editor: TIGIT versus CD226: hegemony or coexistence? Eur J Immunol, 44(1), 307–308.
   Google Scholar
• Grosso JF, Jure-Kunkel MN. (2013). CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunity, 13, 5.
   PubMedGoogle Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. (2015). Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity, 42(2), 344–355.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 369(2), 134–144.
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. (2014). The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell, 26(6), 923–937.
   PubMed Web of Science ®Google Scholar
• Joller N, Hafler JP, Brynedal B, et al. (2011). Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol, 186(3), 1338–1342.
   Google Scholar
• Joller N, Lozano E, Burkett PR, et al. (2014). Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity, 40(4), 569–581.
   PubMed Web of Science ®Google Scholar
• Kalos M, June CH. (2013). Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity, 39(1), 49–60.
   Google Scholar
• Kamran N, Takai Y, Miyoshi J, et al. (2013). Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PloS One, 8(1), e54406.
   PubMed Web of Science ®Google Scholar
• Kerr WG, Colucci F. (2011). Inositol phospholipid signaling and the biology of natural killer cells. J Innate Immunity, 3(3), 249–257.
   Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, et al. (2015). TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest, 125(11), 4053–4062.
   Google Scholar
• Lakshmikanth T, Burke S, Ali TH, et al. (2009). NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119(5), 1251–1263.
   PubMed Web of Science ®Google Scholar
• Levin SD, Taft DW, Brandt CS, et al. (2011). Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol, 41(4), 902–915.
   PubMed Web of Science ®Google Scholar
• Li M, Xia P, Du Y, et al. (2014). T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem, 289(25), 17647–17657.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Li M, et al. (2013). Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ, 20(3), 456–464.
   PubMed Web of Science ®Google Scholar
• Liu W, Almo SC, Zang X. (2016). Co-stimulate or Co-inhibit regulatory T cells, which side to go? Immunol Invest, 1–19.
   Google Scholar
• Lopez M, Aoubala M, Jordier F, et al. (1998). The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood, 92(12), 4602–4611.
   PubMed Web of Science ®Google Scholar
• Lozano E, Dominguez-Villar M, Kuchroo V, et al. (2012). The TIGIT/CD226 axis regulates human T cell function. J Immunol, 188(8), 3869–3875.
   PubMed Web of Science ®Google Scholar
• Lozano E, Joller N, Cao Y, et al. (2013). The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans. J Immunol, 191(7), 3673–3680.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Sylvain A, Thibult ML, et al. (2011). Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest, 121(9), 3609–3622.
   Google Scholar
• Masson D, Jarry A, Baury B, et al. (2001). Overexpression of the CD155 gene in human colorectal carcinoma. Gut, 49(2), 236–240.
   PubMed Web of Science ®Google Scholar
• Murakami N, Riella LV. (2014). Co-inhibitory pathways and their importance in immune regulation. Transplantation, 98(1), 3–14.
   Google Scholar
• Nagumo Y, Iguchi-Manaka A, Yamashita-Kanemaru Y, et al. (2014). Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice. PloS One, 9(11), e112415.
   PubMed Web of Science ®Google Scholar
• Nishiwada S, Sho M, Yasuda S, et al. (2015). Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res, 35(4), 2287–2297.
   PubMed Web of Science ®Google Scholar
• Oshima T, Sato S, Kato J, et al. (2013). Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. Mol Cancer, 12, 60.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. (2014). TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell, 26(6), 785–787.
   PubMed Web of Science ®Google Scholar
• Pende D, Castriconi R, Romagnani P, et al. (2006). Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood, 107(5), 2030–2036.
   PubMed Web of Science ®Google Scholar
• Reymond N, Imbert AM, Devilard E, et al. (2004). DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med, 199(10), 1331–1341.
   PubMed Web of Science ®Google Scholar
• Riley JL. (2009). PD-1 signaling in primary T cells. Immunol Rev, 229(1), 114–125.
   PubMed Web of Science ®Google Scholar
• Rudd CE, Schneider H. (2003). Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol, 3(7), 544–556.
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. (2009). CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev, 229(1), 12–26.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Gayoso I, Bergua JM, et al. (2012). Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol, 90(1), 109–115.
   PubMed Web of Science ®Google Scholar
• Schietinger A, Greenberg PD. (2014). Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol, 35(2), 51–60.
   Google Scholar
• Sharpe AH, Freeman GJ. (2002). The B7-CD28 superfamily. Nat Rev Immunol, 2(2), 116–126.
   PubMed Web of Science ®Google Scholar
• Sharpe AH. (2009). Mechanisms of costimulation. Immunol Rev, 229(1), 5–11.
   Google Scholar
• Shibuya A, Campbell D, Hannum C, et al. (1996). DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity, 4(6), 573–581.
   PubMed Web of Science ®Google Scholar
• Shibuya K, Shirakawa J, Kameyama T, et al. (2003). CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med, 198(12), 1829–1839.
   PubMed Web of Science ®Google Scholar
• Sloan KE, Eustace BK, Stewart JK, et al. (2004). CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer, 4, 73.
   PubMed Web of Science ®Google Scholar
• Soriani A, Zingoni A, Cerboni C, et al. (2009). ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 113(15), 3503–3511.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Rovis TL, Glasner A, et al. (2013). Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol, 43(8), 2138–2150.
   Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. (2009). The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA, 106(42), 17858–17863.
   PubMed Web of Science ®Google Scholar
• Stengel KF, Harden-Bowles K, Yu X, et al. (2012). Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci USA, 109(14), 5399–5404.
   Google Scholar
• Tahara-Hanaoka S, Shibuya K, Kai H, et al. (2006). Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood, 107(4), 1491–1496.
   PubMed Web of Science ®Google Scholar
• Tahara-Hanaoka S, Shibuya K, Onoda Y, et al. (2004). Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol, 16(4), 533–538.
   PubMed Web of Science ®Google Scholar
• Tao L, Song C, Huo C, et al. (2016). Anti-CD155 and anti-CD112 monoclonal antibodies conjugated to a fluorescent mesoporous silica nanosensor encapsulating rhodamine 6G and fluorescein for sensitive detection of liver cancer cells. Analyst, 141(16), 4933–4940.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol Off J Am Soc Clin Oncol, 32(10), 1020–1030.
   PubMed Web of Science ®Google Scholar
• Tsai KK, Daud AI. (2015). Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol, 8(1), 123.
   Google Scholar
• Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, et al. (2004). An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 20(5), 563–575.
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. (2015). Confusing signals: recent progress in CTLA-4 biology. Trends Immunol, 36(2), 63–70.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 369(2), 122–133.
   Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. (2009). The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat immunol, 10(1), 48–57.
   Google Scholar
• Zhang B, Zhao W, Li H, et al. (2016). Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155. Cancer Immunol Immunother CII, 65(3), 305–314.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Maksimovic J, Naselli G, et al. (2013). Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood, 122(16), 2823–2836.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Paniccia A, Schulick AC, et al. (2016). Identification of CD112R as a novel checkpoint for human T cells. J Exp Med, 213(2), 167–176.
   PubMed Web of Science ®Google Scholar